Automate Your Wheel Strategy on NRXPW
With Tiblio's Option Bot, you can configure your own wheel strategy including NRXPW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NRXPW
- Rev/Share 0.0002
- Book/Share -1.5333
- PB -1.7732
- Debt/Equity 0.0
- CurrentRatio 0.2216
- ROIC 0.6499
- MktCap 53025844.0
- FreeCF/Share -0.694
- PFCF -4.6559
- PE -1.8505
- Debt/Assets 0.0
- DivYield 0
- ROE 1.1267
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About NRx Pharmaceuticals, Inc. (NRXPW)
- IPO Date 2017-12-01
- Website https://www.nrxpharma.com
- Industry Biotechnology
- CEO Jonathan C. Javitt
- Employees None
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.